MND team

Bispebjerg Hospital

The MND clinic at Bispebjerg University Hospital provides multidisciplinary care to MND patients from the capital region of Denmark and offers second opinion for ALS patients from other regions. We are currently running several studies and are open to more collaboration regarding randomized placebo controlled studies.

BispHos
Bispebjerg Hospital

Our team consists of five neurologists, a neuropsychologist, a logopedist, clinical and research nurses, a physiotherapist, an occupational therapist, a clinical dietician, and a social counsellor. We closely cooperate with respiratory specialists and with other MND teams in Denmark. All patients are routinely offered genetic testing.

Contact
Location
Nielsine Nielsens Vej 7, 2400 Kopenhagen, Denemarken

Our specialists

Kirsten Svenstrup

Consultant Neurologist, PhD

Kirsten Svenstrup is a member of the MND team of Bispebjerg Hospital […]

Kirsten Svenstrup
Current trials
Recruiting
Phase iii

ATLAS trial

Industry trial
Biogen is conducting a clinical trial to evaluate the efficacy and safety and of an investigational drug for adults who do not have any clinical signs or symptoms of Amyotrophic Lateral Sclerosis (ALS) (that definitely indicate the onset of ALS) but do carry a certain superoxide dismutase 1 (SOD1) gene variant.
Read more
Recruiting
Phase iii

FUSION trial

Industry trial
In this study we investigate the safety and efficacy of the study drug ‘ION363’ for the treatment of ALS caused by mutations in the FUS gene. About 1% to 5% of ALS cases are caused by FUS mutations.
Read more
Active
Phase iii

PHOENIX trial

Industry trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035' for the treatment of ALS.
Read more
Active
Phase iii

ADORE trial

Industry trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Read more
Recruiting
Phase iii

COURAGE-ALS Trial

Industry trial
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
Read more
Active
Phase ii

APL2-ALS-206 Trial

Industry trial
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
Read more
Active
Phase iii

TUDCA-ALS

Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
Read more